Intramuscular myxoma of the left thigh: a rare tumor

SummaryMedullary carcinoma of the thyroid gland is a rare tumor. Its prognosis is mainly linked to surgery, because there is no valid alternative therapy to improve patients outcome. In this report, we discuss the recurrence of such a tumor in a 64-year-old female, focusing on magnetic resonance imaging and positron emission tomography evaluation of this tumor.

Download Full-text

Intramuscular myxoma of the cervical muscles with GNAS mutation

Journal of Neurosurgical Sciences ◽

10.23736/s0390-5616.17.04226-6 ◽

2019 ◽

Vol 63 (4) ◽

Author(s):

Giulia Pilloni ◽

Marco Ajello ◽

Antonio Melcarne ◽

Nicola Marengo ◽

Francesco Zenga ◽

...

Keyword(s):

Intramuscular Myxoma ◽

Cervical Muscles ◽

Gnas Mutation

Download Full-text

THERAPY MODALITIES, PROGNOSTIC FACTORS AND OUTCOME OF THE PRIMARY CERVICAL CARCINOSARCOMA: META-ANALYSIS OF EXTREMELY RARE TUMOR OF CERVIX

10.26226/morressier.597eedbfd462b80296ca09b8 ◽

2017 ◽

Author(s):

Kimyon Comert Gunsu

Keyword(s):

Prognostic Factors ◽

Meta Analysis ◽

Rare Tumor

Download Full-text

Pleomorphic giant cell carcinoma of prostate: Rare tumor with unique clinicopathological, immunohistochemical, and molecular features

Annals of Diagnostic Pathology ◽

10.1016/j.anndiagpath.2021.151719 ◽

2021 ◽

Vol 52 ◽

pp. 151719

Author(s):

Ziad M. El-Zaatari ◽

Jessica S. Thomas ◽

Mukul K. Divatia ◽

Steven S. Shen ◽

Alberto G. Ayala ◽

...

Keyword(s):

Cell Carcinoma ◽

Giant Cell ◽

Rare Tumor ◽

Giant Cell Carcinoma ◽

Molecular Features ◽

Pleomorphic Giant Cell Carcinoma

Download Full-text

Gastric Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Western Center Case Series

Medical Sciences ◽

10.3390/medsci9030047 ◽

2021 ◽

Vol 9 (3) ◽

pp. 47

Author(s):

Marcus Fernando Kodama Pertille Ramos ◽

Marina Alessandra Pereira ◽

Arthur Youssif Mota Arabi ◽

Melissa Mello Mazepa ◽

Andre Roncon Dias ◽

...

Keyword(s):

Gastric Adenocarcinoma ◽

Tumor Size ◽

Lymphovascular Invasion ◽

Comparison Group ◽

Case Series ◽

Clinicopathological Characteristics ◽

Neuroendocrine Neoplasms ◽

Rare Tumor ◽

Term Survival

Background: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) represent a rare tumor composed of adenocarcinoma and neuroendocrine carcinoma components. This study reports a case series of gastric MiNEN and discusses issues related to its diagnosis, management, and outcomes. Methods: We retrospectively analyzed data from patients with gastric MiNEN who underwent surgical resection at our service from 2009 to 2020. Patients with gastric adenocarcinoma served as a comparison group. Clinical, pathologic, and surgical characteristics were compared. Results: During the selected period, 5 gastric MiNEN patients and 597 patients with gastric adenocarcinoma were included. Among the clinical variables, age, sex, BMI, and laboratory exams were similar between the two groups. Only ASA classification was different (p = 0.015). Pathological variables such as tumor size, lymphovascular invasion, number of retrieved lymph nodes, and pTNM staging were also similar between both groups. Lastly, early surgical outcomes and long-term survival did not differ between gastric MiNEN and adenocarcinoma patients. Conclusion: A MiNEN is a rare tumor that represents less than 1% of GC patients undergoing curative treatment, and demonstrated clinicopathological characteristics and outcomes similar to gastric adenocarcinoma.

Download Full-text

A Case of Primary Hepatic Neuroendocrine Tumor and Literature Review

Case Reports in Oncology ◽

10.1159/000510935 ◽

2021 ◽

pp. 90-97

Author(s):

Pak Chiu Wong ◽

Wong Hoi She ◽

Ui Soon Khoo ◽

Tan To Cheung

Keyword(s):

Liver Resection ◽

Neuroendocrine Tumor ◽

Preoperative Diagnosis ◽

Radionuclide Therapy ◽

Tumor Recurrence ◽

Peptide Receptor Radionuclide Therapy ◽

Rare Tumor ◽

Major Liver Resection ◽

Peptide Receptor ◽

Primary Hepatic Neuroendocrine Tumor

We report an unusual presentation of primary hepatic neuroendocrine tumor which was initially misdiagnosed as intrahepatic cholangiocarcinoma. The diagnosis was only revealed after a major liver resection by histopathology. With adjuvant lanreotide injection, the patient survived for more than 16 months after the operation without tumor recurrence. Diagnosis of this rare tumor has been a major challenge and we emphasize the importance of a preoperative diagnosis. Surgical resection remains the mainstay for curative treatment, while peptide receptor radionuclide therapy is an emerging treatment option which has provided promising results.

Download Full-text